Loading...
Although women with BRCA1 mutations have a lifetime risk for breast cancer of 60% to 80%, this risk can be lowered substantially by prophylactic oophorectomy before menopause. Unfortunately, surgical castration can be associated with severe, sometimes disabling, vasomotor symptoms. However, concerns that hormone therapy might increase risk for breast cancer have led to uncertainty about whether BRCA mutation carriers who suffer from vasomotor symptoms after menopause or oophorectomy should use HT.
In a case-control study conducted in a population of postmenopausal BRCA1 mutation carriers at 55 centers in nine countries, investigators enrolled women who had reached menopause without diagnoses of breast cancer or other malignancies. Women who …